Economic factors in formulating a national policy on the prevention by drugs of cardiovascular disease.
Malcolm
L
L
Department of Community Health, Wellington School of Medicine.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000097:blood / Q000191:economics / Q000401:mortality / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D003362:Cost-Benefit Analysis; D004470:Economics, Medical; D005069:Evaluation Studies as Topic; D006291:Health Policy / Q000191:economics*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy / Q000191:economics / Q000401:mortality; D008017:Life Expectancy; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000097:blood
D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D002784:Cholesterol